Formula
Ingredients, dose, claims, stability, cost and regulatory classification.
Industrial platform
From raw material
to batch release.
The operation is conceived as a continuous system: product, process, quality, data, energy, logistics and market.
Pharma
Fewer SKUs.
More execution.
The first phase should prioritise forms and products capable of achieving demand, quality and stable operation, rather than maximising complexity from day one.
P1
Oral solids
Core
Proposed Phase 1P2
Non-sterile liquids
Modular
To validateP3
Sterile products
Complex
Recommended to phaseNutraTech
Revenue must pass through the factory floor.
USD 222 million in Year 5 equals exactly 12 million bottles at USD 18.50. The number becomes investible only when net price, pack, OEE, line balance, channel and demand are evidenced.
Manufacture
Batch size, depositor rate, curing, yield, scrap, OEE and changeovers.
Pack & release
Gummies per bottle, packaging, label, microbiology and batch release.
Sell & collect
KAIROS net price, distributor, retail, freight, rebates, payment and working capital.
Digital architecture
The factory is also a data system.
ERP, MES, LIMS, maintenance, serialization, warehouse and analytics need a common, phased architecture. Technology should not be purchased as a list of brands.
Plan
ERP, planning, procurement, finance e supply chain.
Execute
MES, batch records, equipment data and production control.
Release
LIMS, quality events, deviations, CAPA and stability.
Trace
Warehouse, serialization, product genealogy and market feedback.